Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

@article{Balak2012CutaneousAE,
  title={Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review},
  author={Deepak M. W. Balak and Gerald J. D. Hengstman and Aysun Çakmak and Hok Bing Thio},
  journal={Multiple Sclerosis Journal},
  year={2012},
  volume={18},
  pages={1705 - 1717}
}
Glatiramer acetate and interferon-beta are approved first-line disease-modifying treatments (DMTs) for multiple sclerosis (MS). DMTs can be associated with cutaneous adverse events, which may influence treatment adherence and patient quality of life. In this systematic review, we aimed to provide an overview of the clinical spectrum and the incidence of skin reactions associated with DMTs. A systematic literature search was performed up to May 2011 in Medline, Embase, and Cochrane databases… 
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
TLDR
The prevalence of cutaneous adverse events was high in long-term DMT-treatment and Dermatology-specific, but not generic, QoL was significantly lower among patients with skin reactions compared to those without.
Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis
TLDR
A multiple sclerosis patient treated with interferon-β who developed new-onset psoriasis is presented and it is suggested that skin lesions may serve as biomarkers to allocate MS patients to adequate disease-modifying drugs.
Subcutaneous Interferon Beta Therapy in Multiple Sclerosis Patients – Characterization of Injection Site Reactions and Flu-Like Symptoms in a Daily Practice Setting – Results from the Non-Interventional Study PERFECT
TLDR
Although ISR were experienced by the majority of patients, they rarely resulted in treatment interruption and in this real-world setting, ISR and FLS management was in line with published expert recommendations.
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
TLDR
The results indicate that changing RRMS patients to GA is associated with positive treatment outcomes, and patients improved significantly on measures of fatigue, quality of life, depression, and cognition.
Interferon-beta injection site reactions in patients with multiple sclerosis
TLDR
Injection site reactions (ISRs), featured by erythema, edema, pain, and pruritus, are the most common adverse reactions and it is very important to adopt strategies to minimize ISRs by proper patient education and counseling.
Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique.
TLDR
Delphi responders agreed on the management strategies for FLSs/ISRs and agreed that patient education is critical to set treatment expectations and promote adherence.
Patterns of local site reactions to subcutaneous glatiramer acetate treatment of multiple sclerosis: a clinicopathological study.
TLDR
GA can cause a spectrum of injection site reactions that can be classified into 3 distinct patterns based on their time frame, clinical picture and histological pattern, which reveals that topical treatment with a potent steroid and tacrolimus cream can alleviate the EPN response.
Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis
TLDR
Starting DMT early in the MS disease course has been shown to have a beneficial effect on relapse prevention, and appears to curtail the atrophy and neurodegenerative changes that are now known to begin at disease onset.
The heritage of glatiramer acetate and its use in multiple sclerosis
TLDR
The mechanism of action, clinical efficacy, safety and tolerability of glatiramer acetate are examined to provide suggestions for optimizing the use of this drug in the current MS therapeutic scenario.
An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
TLDR
This report addresses expert recommendations on the management of most relevant adverse effects related to peginterferon beta-1a and other interferon betas, based on literature and interdisciplinary experience.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 142 REFERENCES
Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management
TLDR
Skin reactio ns in response to injectable DMA therapy in MS are generally mild, however, some reactios can evolve into potentially serious lesions culminating in infection, necro sis, and in some circumstances requiring surgical repair.
[Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices].
TLDR
It is concluded that autoinjector use reduces the occurrence of ISR during IFNB-1b therapy in RRMS.
Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b.
TLDR
It is concluded that a vasculitic-like cutaneous reaction to interferon beta-1b may occur long after institution of therapy in some MS patients.
Interferon in relapsing-remitting multiple sclerosis.
TLDR
The efficacy of interferon on exacerbations and disease progression in patients with relapsing remitting MS was modest after one and two years of treatment, and it was not possible to conduct a quantitative analysis beyond two years.
A longitudinal observational study of a cohort of patients with relapsing–remitting multiple sclerosis treated with glatiramer acetate
TLDR
Patients with RRMS to whom β‐interferons cannot be prescribed can benefit from treatment with glatiramer acetate, as mean annualized relapse rates and mean EDSS scores remained stable.
[Cutaneous vasculitis with renal impairment complicating interferon-beta 1a therapy for multiple sclerosis].
TLDR
The etiology of the cutaneous and renal impairment is not formally established but the drug-induced hypothesis is proposed for interferon beta-1a.
Lipoatrophy: a non–reversible complication of subcutaneous interferon–beta 1a treatment of multiple sclerosis
TLDR
A case of manifest lipoatrophy is reported in a patient treated with subcutaneous injections of IFNB-1a, believed to be the first case published.
Vitiligo and multiple sclerosis in a patient treated with interferon beta‐1a: a case report
TLDR
The case of a 33-year-old female patient who developed vitiligo lesions after receiving 22 mcg of subcutaneous recombinant IFN beta-1a therapy three times weekly for relapsing-remitting multiple sclerosis is presented.
[Profile of efficacy and safety in the treatment of remittent-recurrent multiple sclerosis with interferon beta-1b].
TLDR
IFN beta-1b has been well tolerated in the postmarketing period, and a significant decrease in relapses of the disease, however disability has not changed in the first year after treatment.
...
1
2
3
4
5
...